PharmaceuticalOutsourcingQ42020 - 63


AmerisourceBergen Reaches
Agreement with CDC to Support
Access to COVID-19 Vaccine

Independent pharmacies are critical sites of care in their communities

AmerisourceBergen has reached an agreement with the U.S. Centers

independent pharmacies gain access to COVID-19 vaccine. They

year-round and many Americans turn to their local pharmacy for a
variety of immunizations annually, " said Brian Nightengale, President
of Good Neighbor Pharmacy. " We are beyond proud to help our

for Disease Control and Prevention (CDC) to include Good Neighbor

are already poised to join this next phase in the fight against the

Pharmacy and Elevate Provider Network members in the Federal

coronavirus and continue to support their communities. "

Pharmacy Partnership Strategy for COVID-19 Vaccination.

This effort will help jurisdictions augment access to COVID-19

To support access, AmerisourceBergen will serve as a network

vaccine when supply increases. With more than 90 percent of people

administrator and place orders with the CDC on behalf of qualified

living within 5 miles of a community pharmacy, pharmacies have

and eligible Good Neighbor Pharmacy and Elevate Provider Network

unique reach and ability to provide access to COVID-19 vaccine

members. AmerisourceBergen will receive a direct allocation of

and support broad vaccination efforts. This program will provide

COVID-19 vaccine for independent retail pharmacy customers once

critical vaccination services for the U.S. population, with vaccine

there is adequate supply of COVID-19 vaccine to support broader

administered at community pharmacy locations at no cost to

inoculation efforts and vaccination is recommended for individuals

recipients. The program will be implemented in close coordination

beyond the initial critical populations. COVID-19 vaccine will be

with jurisdictions to enable optimal COVID-19 vaccination coverage

distributed by the CDC's central distributor.

and vaccine access nationwide.

" Independent community pharmacies have been fearless and have

Good Neighbor Pharmacy is AmerisourceBergen's independent

risen to every challenge that COVID-19 has presented this past year.

community pharmacy network.

Statement of Ownership, Management, and Circulation
(Requester Publications Only)

1. Publication Title

2. Publication Number

Pharmaceutical Outsourcing

4. Issue Frequency


5. Number of Issues Published Annually

January/February/March, April/May/June, July/August/September, October/November/December


7. Complete Mailing Address of Known Office of Publication (Not printer) (Street, city, county, state, and ZIP+4)

3. Filing Date

October 1, 2020

6. Annual Subscription Price
Contact Person
Andy Miller

395 Oyster Point Blvd., Suite 300; South San Francisco, CA 94080
8. Complete Mailing Address of Headquarters or General Business Office of Publisher (Not printer)
395 Oyster Point Blvd., Suite 300; South San Francisco, CA 94080
9. Full Names and Complete Mailing Addresses of Publisher, Editor, and Managing Editor (Do not leave blank)
Publisher (Name and complete mailing address)
Laura Rice, 395 Oyster Point Blvd., Suite 300; South San Francisco, CA 94080
Editor (Name and complete mailing address)
Mike Auerbach, 395 Oyster Point Blvd., Suite 300; South San Francisco, CA 94080
Managing Editor (Name and complete mailing address)

10. (Do not leave blank If the publication is owned by a corporation, give the name and address of the corporation immediately followed by the
names and addresses of all stockholders owning or holding 1 percent or more of the total amount of stock. If not owned by a corporation, give the
names and addresses of the individual owners. If owned by a partnership or other unincorporated firm, give its name and address as well as those of
each individual owner. If the publication is published by a nonprofit organization, give its name and address.)
Full Name
Complete Mailing Address
CompareNetworks, Inc

395 Oyster Point Blvd., Suite 300; South San Francisco, CA 94080

11 Known Bondholders, Mortgagees, and Other Security Holders Owning or
Holding 1 Percent or More of Total Amount of Bonds, Mortgages, or
Other Securities. If none, check box ------------------------------------------------------------------------------------- Q None


Full Name

Complete Mailing Address

12. Tax Status (For completion by nonprofit organizations authorized to maiI at nonprofit rates) (Check one)
The purpose, function, and nonprofit status of this organization and the exempt status for federal income tax purposes:
Q Has Not Changed During Preceding 12 Months
c Has Changed During Preceding 12 Months (Publisher must submit explanation of change with this statement)
PS Form 3526-R, July 2014

PSN: 7530-09-000-8855 |


| October/November/December 2020


Table of Contents for the Digital Edition of PharmaceuticalOutsourcingQ42020

Editor's Message
Editorial Advisory Board
CN Perspectives
Social Media Connections
Insider Insight - Price
Insider Insight - Ventura
Contract Manufacturing
Supply Chain
Contract Manufacturing
Interview with Yourway
Supply Chain
Clinical Trials
Supply Chain
Analytical Testing
Supply Chain
Clinical Trials
Analytical Testing
Horizon Lines
Industry News
Advertiser's Index
PharmaceuticalOutsourcingQ42020 - Cover1
PharmaceuticalOutsourcingQ42020 - Cover2
PharmaceuticalOutsourcingQ42020 - 1
PharmaceuticalOutsourcingQ42020 - Editor's Message
PharmaceuticalOutsourcingQ42020 - 3
PharmaceuticalOutsourcingQ42020 - 4
PharmaceuticalOutsourcingQ42020 - 5
PharmaceuticalOutsourcingQ42020 - Editorial Advisory Board
PharmaceuticalOutsourcingQ42020 - 7
PharmaceuticalOutsourcingQ42020 - CN Perspectives
PharmaceuticalOutsourcingQ42020 - Social Media Connections
PharmaceuticalOutsourcingQ42020 - Insider Insight - Price
PharmaceuticalOutsourcingQ42020 - 11
PharmaceuticalOutsourcingQ42020 - Insider Insight - Ventura
PharmaceuticalOutsourcingQ42020 - 13
PharmaceuticalOutsourcingQ42020 - Contract Manufacturing
PharmaceuticalOutsourcingQ42020 - 15
PharmaceuticalOutsourcingQ42020 - 16
PharmaceuticalOutsourcingQ42020 - 17
PharmaceuticalOutsourcingQ42020 - Supply Chain
PharmaceuticalOutsourcingQ42020 - 19
PharmaceuticalOutsourcingQ42020 - Contract Manufacturing
PharmaceuticalOutsourcingQ42020 - 21
PharmaceuticalOutsourcingQ42020 - Interview with Yourway
PharmaceuticalOutsourcingQ42020 - 23
PharmaceuticalOutsourcingQ42020 - Supply Chain
PharmaceuticalOutsourcingQ42020 - 25
PharmaceuticalOutsourcingQ42020 - 26
PharmaceuticalOutsourcingQ42020 - 27
PharmaceuticalOutsourcingQ42020 - 28
PharmaceuticalOutsourcingQ42020 - 29
PharmaceuticalOutsourcingQ42020 - Clinical Trials
PharmaceuticalOutsourcingQ42020 - 31
PharmaceuticalOutsourcingQ42020 - 32
PharmaceuticalOutsourcingQ42020 - Roundtable
PharmaceuticalOutsourcingQ42020 - 34
PharmaceuticalOutsourcingQ42020 - 35
PharmaceuticalOutsourcingQ42020 - Supply Chain
PharmaceuticalOutsourcingQ42020 - 37
PharmaceuticalOutsourcingQ42020 - 38
PharmaceuticalOutsourcingQ42020 - 39
PharmaceuticalOutsourcingQ42020 - Analytical Testing
PharmaceuticalOutsourcingQ42020 - 41
PharmaceuticalOutsourcingQ42020 - 42
PharmaceuticalOutsourcingQ42020 - 43
PharmaceuticalOutsourcingQ42020 - Supply Chain
PharmaceuticalOutsourcingQ42020 - 45
PharmaceuticalOutsourcingQ42020 - 46
PharmaceuticalOutsourcingQ42020 - 47
PharmaceuticalOutsourcingQ42020 - Clinical Trials
PharmaceuticalOutsourcingQ42020 - 49
PharmaceuticalOutsourcingQ42020 - 50
PharmaceuticalOutsourcingQ42020 - Analytical Testing
PharmaceuticalOutsourcingQ42020 - 52
PharmaceuticalOutsourcingQ42020 - 53
PharmaceuticalOutsourcingQ42020 - Horizon Lines
PharmaceuticalOutsourcingQ42020 - 55
PharmaceuticalOutsourcingQ42020 - 56
PharmaceuticalOutsourcingQ42020 - 57
PharmaceuticalOutsourcingQ42020 - Industry News
PharmaceuticalOutsourcingQ42020 - 59
PharmaceuticalOutsourcingQ42020 - 60
PharmaceuticalOutsourcingQ42020 - 61
PharmaceuticalOutsourcingQ42020 - 62
PharmaceuticalOutsourcingQ42020 - 63
PharmaceuticalOutsourcingQ42020 - Advertiser's Index
PharmaceuticalOutsourcingQ42020 - Cover3
PharmaceuticalOutsourcingQ42020 - Cover4